Compare Enveric Biosciences Inc (ENVB) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Verisign, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Verisign, Inc. trades at $274.97 (market cap $24.62B). The key difference: Verisign, Inc. is far larger — about 4627.8× Enveric Biosciences Inc's market cap, and Verisign, Inc. pays a 1.2% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | VRSN | |
|---|---|---|
Market Cap | $5.32M | $24.62B |
Sector | Health | Technology |
52-Week High | $17.40 | $310.00 |
52-Week Low | $1.28 | $211.49 |
Enterprise Value | $408.82K | $25.86B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
VeriSign (VRSN) trades at $268.85, down 0.54% today, with a bullish technical outlook and strong fundamentals. The stock shows consistent revenue growth, reaching $1.66B in 2025, and maintains high profit margins near 50%. Recent Q1 2026 earnings beat expectations at $2.34 EPS, though Q4 2025 missed. Analyst consensus is bullish with a $325.25 price target, and technical indicators suggest support at $265 with resistance at $271.
VRSN offers stable growth driven by its monopoly on .com and .net domains, but faces risks from AI disruption and contract renewals. The stock is fairly valued with a P/E of 29.89, and institutional sentiment is positive. Key risks include high debt levels and competitive threats, yet the company's cash flow and dividend payments support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
